Tethered ligand‐derived peptides of proteinase‐activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat T cells

Summary Proteinase‐activated receptors (PARs) can activate a number of signalling events, including T‐cell signal‐transduction pathways. Recent data suggest that the activation of PARs 1, 2 and 3 in Jurkat T‐leukaemic cells induces tyrosine phosphorylation of the haematopoietic signal transducer pro...

Full description

Saved in:
Bibliographic Details
Published inImmunology Vol. 112; no. 2; pp. 183 - 190
Main Authors Hansen, Kristina K., Saifeddine, Mahmoud, Hollenberg, Morley D.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.06.2004
Blackwell Science Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Proteinase‐activated receptors (PARs) can activate a number of signalling events, including T‐cell signal‐transduction pathways. Recent data suggest that the activation of PARs 1, 2 and 3 in Jurkat T‐leukaemic cells induces tyrosine phosphorylation of the haematopoietic signal transducer protein, VAV1. To activate the PARs, this study used the agonist peptides SFLLRNPNDK, SLIGKVDGTS and TFRGAPPNSF, which are based on the sequences of the tethered ligand sequences of human PARs 1, 2 and 3, respectively. Here, we show that peptides based on either the human or murine PAR3‐derived tethered ligand sequences (TFRGAP‐NH2 or SFNGGP‐NH2) do not activate PAR3, but rather activate PARs 1 and 2, either in Jurkat or in other PAR‐expressing cells. Furthermore, whilst thrombin activates only Jurkat PAR1, trypsin activates both PARs 1 and 2 and also disarms Jurkat PAR1 for thrombin activation. We conclude therefore that in Jurkat or related T cells, signalling via PARs that can affect VAV1 phosphorylation is mediated via PAR 1 or 2, or both, and that distinct serine proteinases may potentially differentially affect T‐cell function in the settings of inflammation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0019-2805
1365-2567
DOI:10.1111/j.1365-2567.2004.01870.x